Cognition Therapeutics Will Participate in the Roth Healthcare Opportunities Conference
Cognition Therapeutics (NASDAQ: CGTX), a clinical-stage company developing drugs for neurodegenerative disorders, announced its participation in the 3rd Annual Roth Healthcare Opportunities Conference on October 9, 2024. The company's president and CEO, Lisa Ricciardi, will take part in a panel discussion titled Frontiers in Neuroscience.
Additionally, Ms. Ricciardi will host one-on-one investor meetings to discuss recent achievements and clinical development plans for CT1812, Cognition's lead candidate for treating Alzheimer's disease, dementia with Lewy bodies, and dry age-related macular degeneration. Interested investors can register for the conference through their Roth Capital Partners' sales representative.
Cognition Therapeutics (NASDAQ: CGTX), una compagnia in fase clinica che sviluppa farmaci per i disturbi neurodegenerativi, ha annunciato la sua partecipazione alla 3ª Conferenza Annuale delle Opportunità Sanitarie Roth, che si terrà il 9 ottobre 2024. La presidente e CEO dell'azienda, Lisa Ricciardi, parteciperà a una discussione di panel intitolata Frontiere nelle Neuroscienze.
Inoltre, la signora Ricciardi ospiterà incontri individuali con gli investitori per discutere i risultati recenti e i piani di sviluppo clinico per CT1812, il principale candidato di Cognition per il trattamento dell'Alzheimer, della demenza a corpi di Lewy e della maculopatia secca legata all'età. Gli investitori interessati possono registrarsi per la conferenza attraverso il rappresentante di vendita di Roth Capital Partners.
Cognition Therapeutics (NASDAQ: CGTX), una empresa en etapa clínica que desarrolla medicamentos para trastornos neurodegenerativos, anunció su participación en la 3ª Conferencia Anual de Oportunidades en Salud Roth el 9 de octubre de 2024. La presidenta y CEO de la compañía, Lisa Ricciardi, participará en una discusión de panel titulada Fronteras en Neurociencia.
Además, la Sra. Ricciardi llevará a cabo reuniones individuales con inversores para discutir los logros recientes y los planes de desarrollo clínico para CT1812, el candidato principal de Cognition para el tratamiento de la enfermedad de Alzheimer, la demenza con cuerpos de Lewy y la degeneración macular seca relacionada con la edad. Los inversores interesados pueden registrarse para la conferencia a través de su representante de ventas de Roth Capital Partners.
인지 치료학 (NASDAQ: CGTX)는 신경퇴행성 질환을 위한 약물을 개발하는 임상 단계 기업으로, 2024년 10월 9일에 열리는 제3회 로스 헬스케어 기회 컨퍼런스에 참여한다고 발표했습니다. 회사의 대통령이자 CEO인 리사 리차르디가 신경과학의 최전선이라는 제목의 패널 토론에 참여할 예정입니다.
또한, 리차르디는 투자자와의 1대1 회의를 주최하여 CT1812에 대한 최근 성과와 임상 개발 계획에 대해 논의할 것입니다. 알츠하이머병, 루이체 치매, 건성 노인성 황반변성 치료를 위한 인지 치료학의 주요 후보입니다. 관심 있는 투자자는 로스 캐피탈 파트너의 영업 대표를 통해 컨퍼런스에 등록할 수 있습니다.
Cognition Therapeutics (NASDAQ: CGTX), une entreprise en phase clinique développant des médicaments pour les troubles neurodégénératifs, a annoncé sa participation à la 3e Conférence Annuelle des Opportunités de Santé Roth prévue le 9 octobre 2024. La présidente et PDG de l’entreprise, Lisa Ricciardi, participera à une discussion en panel intitulée Frontières en Neurosciences.
De plus, Mme Ricciardi animera des réunions individuelles avec des investisseurs pour discuter des réalisations récentes et des plans de développement clinique pour CT1812, le candidat principal de Cognition pour le traitement de la maladie d'Alzheimer, de la démence à corps de Lewy et de la dégénérescence maculaire liée à l'âge sèche. Les investisseurs intéressés peuvent s'inscrire à la conférence par l'intermédiaire de leur représentant commercial chez Roth Capital Partners.
Cognition Therapeutics (NASDAQ: CGTX), ein klinisches Unternehmen, das Medikamente für neurodegenerative Erkrankungen entwickelt, hat seine Teilnahme an der 3. jährlichen Roth Healthcare Opportunities Conference am 9. Oktober 2024 angekündigt. Die Präsidentin und CEO des Unternehmens, Lisa Ricciardi, wird an einer Podiumsdiskussion mit dem Titel Grenzen der Neurowissenschaften teilnehmen.
Darüber hinaus wird Frau Ricciardi persönliche Investorengespräche führen, um über die jüngsten Erfolge und die klinischen Entwicklungspläne für CT1812, Cognitions Hauptkandidaten zur Behandlung von Alzheimer, Demenzen mit Lewy-Körpern und trockener altersbedingter Makuladegeneration zu sprechen. Interessierte Investoren können sich über den Verkaufsvertreter von Roth Capital Partners für die Konferenz registrieren.
- Participation in a prominent healthcare conference, potentially increasing visibility and investor interest
- Opportunity for one-on-one investor meetings, which could lead to increased investment or partnerships
- Development of CT1812 for multiple neurodegenerative conditions, indicating a diverse pipeline
- None.
PURCHASE, N.Y., Oct. 02, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical-stage company developing drugs to treat neurodegenerative disorders, today announced the Company’s president and CEO Lisa Ricciardi will participate in a panel discussion titled Frontiers in Neuroscience during the 3rd Annual Roth Healthcare Opportunities Conference on October 9, 2024.
Ms. Ricciardi also will host one-on-one investor meetings during which she will highlight recent achievements and clinical development plans for CT1812, the Company's lead candidate for the treatment of Alzheimer’s disease, dementia with Lewy bodies, and dry age-related macular degeneration. Investors interested in participating in the event and meeting with the Cognition team should contact their Roth Capital Partners’ sales representative to register for the conference.
About Cognition Therapeutics, Inc.
Cognition Therapeutics, Inc., is a clinical-stage biopharmaceutical company discovering and developing innovative, small molecule therapeutics targeting age-related degenerative disorders of the central nervous system and retina. We currently are investigating our lead candidate CT1812 in clinical programs in Alzheimer’s disease, dementia with Lewy bodies (DLB) and dry age-related macular degeneration (dry AMD). We believe CT1812 and our pipeline of σ-2 receptor modulators can regulate pathways that are impaired in these diseases that are functionally distinct from other approaches for the treatment of degenerative diseases. More about Cognition Therapeutics and our pipeline can be found at https://cogrx.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. All statements contained in this press release or made during the conference, other than statements of historical facts or statements that relate to present facts or current conditions, including but not limited to, statements regarding our product candidates, including CT1812, and any expected or implied benefits or results, including that initial clinical results observed with respect to CT1812 will be replicated in later trials and our clinical development plans, including statements regarding our clinical studies of CT1812 and any analyses of the results therefrom, are forward-looking statements. These statements, including statements relating to the timing and expected results of our clinical trials, involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “may,” might,” “will,” “should,” “expect,” “plan,” “aim,” “seek,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “forecast,” “potential” or “continue” or the negative of these terms or other similar expressions. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition, and results of operations. These forward-looking statements speak only as of the date of this press release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond our control. Factors that may cause actual results to differ materially from current expectations include, but are not limited to: competition; our ability to secure new (and retain existing) grant funding; our ability to grow and manage growth, maintain relationships with suppliers and retain our management and key employees; our ability to successfully advance our current and future product candidates through development activities, preclinical studies and clinical trials and costs related thereto; uncertainties inherent in the results of preliminary data, pre-clinical studies and earlier-stage clinical trials being predictive of the results of early or later-stage clinical trials; the timing, scope and likelihood of regulatory filings and approvals, including regulatory approval of our product candidates; changes in applicable laws or regulations; the possibility that the we may be adversely affected by other economic, business or competitive factors, including ongoing economic uncertainty; our estimates of expenses and profitability; the evolution of the markets in which we compete; our ability to implement our strategic initiatives and continue to innovate our existing products; our ability to defend our intellectual property; the impacts of ongoing global and regional conflicts on our business, supply chain and labor force; and the risks and uncertainties described more fully in the “Risk Factors” section of our annual and quarterly reports filed with the Securities & Exchange Commission and are available at www.sec.gov. These risks are not exhaustive and we face both known and unknown risks. You should not rely on these forward-looking statements as predictions of future events. The events and circumstances reflected in our forward-looking statements may not be achieved or occur, and actual results could differ materially from those projected in the forward-looking statements. Moreover, we operate in a dynamic industry and economy. New risk factors and uncertainties may emerge from time to time, and it is not possible for management to predict all risk factors and uncertainties that we may face. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.
| Contact Information: Cognition Therapeutics, Inc. info@cogrx.com | Casey McDonald (media) Tiberend Strategic Advisors, Inc. cmcdonald@tiberend.com | Mike Moyer (investors) LifeSci Advisors mmoyer@lifesciadvisors.com |
This press release was published by a CLEAR® Verified individual.
FAQ
When is Cognition Therapeutics (CGTX) participating in the Roth Healthcare Opportunities Conference?
What will Cognition Therapeutics' CEO discuss during the Roth Healthcare Opportunities Conference?
What conditions is Cognition Therapeutics' (CGTX) lead candidate CT1812 being developed to treat?
How can investors participate in meetings with Cognition Therapeutics (CGTX) at the Roth conference?
